Aclarion (ACON) Q3 2026 earnings summary

Executive summary

• Q3 revenue rose 78.1% YoY to $33,733, driven by higher Nociscan report volumes in the UK after local coverage decisions.

• Nine-month revenue increased 39.9% YoY to $80,081, while net loss widened to $8.22M from $5.34M as operating expenses increased.

Financial highlights

• Q3 gross profit was $14,796 versus $4,386; operating loss was $2.75M versus $1.83M, and net loss was $2.62M versus $1.71M.

• 9M gross profit was $26,843 versus $5,037; operating loss was $8.64M versus $5.06M, and net loss was $8.22M versus $5.34M.

• Q3 operating expenses grew to $2.77M from $1.84M; 9M operating expenses rose to $8.67M from $5.06M.

• Cash, cash equivalents and restricted cash were $14.21M at September 30, 2026, versus $12.04M at year-end 2025.

Outlook and guidance

• Existing cash is expected to fund operating and capital requirements for at least 12 months from issuance of the financial statements; estimates depend on assumptions and additional capital may be needed.

• Revenue is expected to increase as additional insurance payors are added and scan volumes grow; sales salaries are expected to remain elevated in Q4 2026.

• R&D expense is expected to rise with Nociscan 3.0 development; CLARITY Trial expense is expected to increase as enrollment expands.